source
- GSK launches three-year cost-cutting plan as new CEO targets R&D efficiencyGSK announced a three-year restructuring program designed to cut costs and sharpen focus on its advanced assets. The plan was presented by CEO Luke Miels, who has been in the role for just over si…
- Altimmune's GLP-1/glucagon shot reduces drinking in Phase 2 alcohol use disorder trialAltimmune announced results from its mid‑stage Phase 2 RECLAIM trial evaluating pemvidutide, a GLP‑1/glucagon dual agonist, in patients with moderate‑to‑severe alcohol use disorder. The trial comp…